Cargando…

In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus

LCB01-0648 is a novel oxazolidinone compound that shows potent antibacterial activities against most Gram-positive cocci, including the multi-drug resistant Staphylococcus aureus. In this study, in vivo activity of LCB01-0699, a LCB01-0648 prodrug, against S. aureus was evaluated in comparison with...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Sang-Hun, Park, Hee-Soo, Lee, Jun-Hyung, Baek, Sung-Yun, Chae, Sang-Eun, Oh, Kyuman, Cho, Young Lag, Kwak, Jin-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149760/
https://www.ncbi.nlm.nih.gov/pubmed/29186032
http://dx.doi.org/10.3390/molecules22122096
_version_ 1783356862748426240
author Oh, Sang-Hun
Park, Hee-Soo
Lee, Jun-Hyung
Baek, Sung-Yun
Chae, Sang-Eun
Oh, Kyuman
Cho, Young Lag
Kwak, Jin-Hwan
author_facet Oh, Sang-Hun
Park, Hee-Soo
Lee, Jun-Hyung
Baek, Sung-Yun
Chae, Sang-Eun
Oh, Kyuman
Cho, Young Lag
Kwak, Jin-Hwan
author_sort Oh, Sang-Hun
collection PubMed
description LCB01-0648 is a novel oxazolidinone compound that shows potent antibacterial activities against most Gram-positive cocci, including the multi-drug resistant Staphylococcus aureus. In this study, in vivo activity of LCB01-0699, a LCB01-0648 prodrug, against S. aureus was evaluated in comparison with that of Linezolid. The results of the systemic infection study demonstrated that LCB01-0699 was more potent than Linezolid against methicillin-susceptible and -resistant S. aureus strains. The in vivo efficacy of LCB01-0699 against methicillin-susceptible and -resistant S. aureus strains in a skin infection model showed more potent activity than Linezolid. LCB01-0699 shows potent in vivo activity against methicillin-susceptible and -resistant S. aureus strains, suggesting that LCB01-0699 would be a novel candidate for the treatment of these infectious diseases caused by S. aureus.
format Online
Article
Text
id pubmed-6149760
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61497602018-11-13 In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus Oh, Sang-Hun Park, Hee-Soo Lee, Jun-Hyung Baek, Sung-Yun Chae, Sang-Eun Oh, Kyuman Cho, Young Lag Kwak, Jin-Hwan Molecules Article LCB01-0648 is a novel oxazolidinone compound that shows potent antibacterial activities against most Gram-positive cocci, including the multi-drug resistant Staphylococcus aureus. In this study, in vivo activity of LCB01-0699, a LCB01-0648 prodrug, against S. aureus was evaluated in comparison with that of Linezolid. The results of the systemic infection study demonstrated that LCB01-0699 was more potent than Linezolid against methicillin-susceptible and -resistant S. aureus strains. The in vivo efficacy of LCB01-0699 against methicillin-susceptible and -resistant S. aureus strains in a skin infection model showed more potent activity than Linezolid. LCB01-0699 shows potent in vivo activity against methicillin-susceptible and -resistant S. aureus strains, suggesting that LCB01-0699 would be a novel candidate for the treatment of these infectious diseases caused by S. aureus. MDPI 2017-11-29 /pmc/articles/PMC6149760/ /pubmed/29186032 http://dx.doi.org/10.3390/molecules22122096 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Oh, Sang-Hun
Park, Hee-Soo
Lee, Jun-Hyung
Baek, Sung-Yun
Chae, Sang-Eun
Oh, Kyuman
Cho, Young Lag
Kwak, Jin-Hwan
In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus
title In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus
title_full In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus
title_fullStr In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus
title_full_unstemmed In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus
title_short In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus
title_sort in vivo activity of lcb 01-0699, a prodrug of lcb 01-0648, against staphylococcus aureus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149760/
https://www.ncbi.nlm.nih.gov/pubmed/29186032
http://dx.doi.org/10.3390/molecules22122096
work_keys_str_mv AT ohsanghun invivoactivityoflcb010699aprodrugoflcb010648againststaphylococcusaureus
AT parkheesoo invivoactivityoflcb010699aprodrugoflcb010648againststaphylococcusaureus
AT leejunhyung invivoactivityoflcb010699aprodrugoflcb010648againststaphylococcusaureus
AT baeksungyun invivoactivityoflcb010699aprodrugoflcb010648againststaphylococcusaureus
AT chaesangeun invivoactivityoflcb010699aprodrugoflcb010648againststaphylococcusaureus
AT ohkyuman invivoactivityoflcb010699aprodrugoflcb010648againststaphylococcusaureus
AT choyounglag invivoactivityoflcb010699aprodrugoflcb010648againststaphylococcusaureus
AT kwakjinhwan invivoactivityoflcb010699aprodrugoflcb010648againststaphylococcusaureus